pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

67 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints918BioPharma Dive354BioSpace335Fierce Biotech314onclive165raps111globenewswire health
therapy area
allOncology8107Rare Disease1930Cardiology1873Immunology1548Hematology1353Vaccines1253Pulmonology1252Psychiatry & CNS
  • BMC Medical recalls 20,160 Luna G3 APAP devices over firmware defect
    On July 15 2026 BMC Medical Co., Ltd. in Beijing reported to the FDA a recall of 20,160 Luna G3 APAP (Model LG3600) devices distributed in the United States because the installed firmware version G…
    fda recalls · 5d agoCRLNegative↗ source
  • B. Braun recalls three lots of 0.9% Sodium Chloride injection due to zinc oxide particles
    B. Braun Medical Inc announced a voluntary recall of three lots of its 0.9% Sodium Chloride Injection USP, 100 mL, packaged in a 150 mL PAB® container. The recall was triggered after testing ident…
    fda recalls · 8d agoCRLNegative↗ source
← prev
page 1 of 3
next →
73
fda recalls71
fda medwatch62
fda press38
886
Ophthalmology520
Pain501
Endocrinology & Metabolism494
Infectious Disease457
  • American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility
    FOR IMMEDIATE RELEASE – September 3, 2026 – New Albany, OH, American Regent, Inc. is conducting a nationwide voluntary recall of three lots of Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) mult…
    fda recalls · 8d agoRegulatoryNeutral↗ source
  • Baxter Recalls One Lot of 70% Dextrose Injection Over Stainless Steel Particulate Risk
    Baxter International announced a voluntary recall of a single lot of its 70% Dextrose Injection after detecting potential stainless steel particles in the solution. The presence of these particles…
    fda recalls · 17d agoCRLNegative↗ source
  • B. Braun voluntarily recalls one lot of Excel Lactated Ringers IV solution over particulate contamination
    B. Braun Medical Inc announced a voluntary recall of a specific lot of its Excel Lactated Ringers Injection, a 1000 mL IV solution, after detecting particulate matter in the product. Laboratory an…
    fda recalls · 23d agoCRLNegative↗ source
  • FDA schedules hearing on Concerta generic withdrawal as Ivonescimab secures first-line lung cancer indication in China
    The U.S. Food and Drug Administration has granted a hearing to consider the withdrawal of a generic version of Concerta. The hearing will address regulatory concerns surrounding the product. In Ch…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Lilly expands access to its experimental obesity therapy while Jazz pulls Zepzelca's second-line lung cancer use
    Lilly announced it will broaden the expanded‑access program for its obesity drug that has not yet received regulatory approval, allowing more patients to receive the treatment under a compassionate…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Baxter recalls cefazolin injection after cardboard particles detected
    Baxter International announced a voluntary nationwide recall of lot LD175708 of its cefazolin in dextrose injection, a single‑dose 100 ml infusion bag. The recall was prompted by a report that car…
    fda recalls · 1mo agoCRLNegative↗ source
  • Baxter voluntarily recalls Cefazolin in Dextrose injection after cardboard particles found
    Baxter International announced a voluntary nationwide recall of Lot LD175708 of its Cefazolin in Dextrose Injection, a single-dose infusion bag. The recall follows a report that cardboard particle…
    fda recalls · 1mo agoCRLNegative↗ source
  • Understanding MET Alterations in Non‑Small Cell Lung Cancer and Emerging Targeted Treatment Options
    The article outlines the primary MET alterations observed in non‑small cell lung cancer, focusing on gene amplification and exon 14 skipping mutations. It explains that these MET changes frequentl…
    onclive · 4mo agoNeutral↗ source
  • TROP2 scoring and MTAP loss emerge as key biomarkers for NSCLC treatment decisions
    Researchers are highlighting two molecular features-TROP2 expression and loss of the MTAP enzyme-as potential guides for therapy in non‑small cell lung cancer. Quantitative scoring of TROP2 by pat…
    onclive · 4mo agoNeutral↗ source
  • UCSF receives $100 million gift to fund capital projects, cancer research and hospital modernization
    Longtime supporters Kathy Chiao and Kenneth Hao have pledged $100 million to the University of California, San Francisco. The commitment is intended to address the university’s most urgent capital…
    onclive · 4mo agoDealPositive↗ source
  • Oncologist Charles Blanke reflects on cancer research journey and push for medical aid in dying
    The latest episode of the "How This Is Building Me" podcast features D. Ross Camidge, MD, PhD, speaking with Charles D. Blanke, MD, a professor at Oregon Health & Science University. The conversati…
    onclive · 4mo agoPositive↗ source
  • Immunotherapy trials like PODIUM-303 are reshaping treatment for squamous cell anal cancer, says Dr Parikh
    Dr Aparna R. Parikh, an oncologist at Massachusetts General Hospital and Harvard professor, highlighted the growing feasibility of immunotherapy studies in squamous cell anal carcinoma (SCAC). She…
    onclive · 4mo agoPositive↗ source
  • Fox Chase Cancer Center and Labcorp launch study of ultra-sensitive blood test for early-stage lung cancer recurrence
    Fox Chase Cancer Center and Labcorp announced a new clinical trial to evaluate a tumor-informed, whole-genome sequencing ctDNA minimal residual disease (MRD) assay for early-stage non-small cell lu…
    onclive · 4mo agoPositive↗ source
  • Experts discuss emerging MET-driven resistance data shaping second-line therapy for EGFR-mutated lung cancer
    In a recent video segment, Dr. Jacob Sands sits down with Dr. Heather Wakelee to talk about the impact of new findings on MET-driven resistance in EGFR‑mutated non‑small cell lung cancer. The conv…
    onclive · 4mo agoNeutral↗ source
  • Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatment
    Therapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction. Expe…
    onclive · 4mo agoNeutral↗ source
  • Delayed and re-emergent immune-related adverse events can persist years after melanoma checkpoint therapy, says expert
    Dr. Michael A. Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, explained that immune checkpoint inhibitors (ICIs) for melanoma have a distinct toxicity profile comp…
    onclive · 4mo agoNeutral↗ source
  • Experts discuss emerging role of TROP2-directed ADCs in EGFR-mutated lung cancer
    The segment, part of a series on EGFR‑mutated non‑small cell lung cancer, featured Dr. Jacob Sands together with Drs. Heather Wakelee and Alissa Cooper. They explained that TROP2‑directed antibody…
    onclive · 4mo agoNeutral↗ source
  • Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollment
    Dr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…
    onclive · 4mo agoNeutral↗ source
  • ctDNA testing shows promise for renal cell carcinoma and germ cell tumors despite current limitations
    Experts discussed how circulating tumor DNA (ctDNA) monitoring, long used in bladder cancer, is being explored for renal cell carcinoma (RCC) and germ cell tumors. In RCC, low tumor shedding has l…
    onclive · 4mo agoNeutral↗ source
  • ctDNA monitoring guides immunotherapy decisions in metastatic urothelial cancer
    Experts discussed how circulating tumor DNA (ctDNA) testing is being used to follow patients with metastatic urothelial carcinoma and to help shape immunotherapy choices. They noted that a rapid d…
    onclive · 4mo agoPositive↗ source
  • Experts discuss when to start therapy for pediatric low‑grade glioma, weighing chemo, MEK inhibitors and family factors
    In a recent discussion, pediatric neuro‑oncologists examined how to decide when to begin treatment for low‑grade glioma in children. They highlighted the need to balance chemotherapy and MEK inhibi…
    onclive · 4mo agoNeutral↗ source
  • Dr Randall explains rationale for CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor trial
    Dr Randall, a professor at UC Davis Comprehensive Cancer Center, discussed the clinical reasoning behind testing the selective CSF-1R inhibitor pimicotinib (ABSK021) for tenosynovial giant cell tum…
    onclive · 4mo agoNeutral↗ source
  • Experts discuss how real-world patient factors shape first-line renal cell carcinoma treatment choices
    Dr. Elizabeth Plimack and Dr. Yasser Ged appeared in a recent segment to talk about first-line treatment selection for renal cell carcinoma. They explained that beyond clinical trial results, real…
    onclive · 4mo agoNeutral↗ source